Segment Data (Tables)

3 Months Ended

Dec. 31, 2013

Segment Reporting [Abstract]

Financial Information for Company's Segments

Financial information for the Company’s segments was as follows:

	Three Months Ended December 31,
	2013			2012
Revenues (A)
Medical	$	1,064		$	983
Diagnostics		672			652
Biosciences		279			265
Total Revenues	$	2,015		$	1,900
Segment Operating Income
Medical	$	300		$	288
Diagnostics		162			170
Biosciences		66			65
Total Segment Operating Income		528			523
Unallocated Items (B)		(170	)		(158	)
Income from Continuing Operations Before Income Taxes	$	359		$	366

(A) Intersegment revenues are not material.

(B) Includes primarily interest, net; foreign exchange; corporate expenses; and share-based compensation expense.

Revenues by Organizational Units

	Three Months Ended December 31,
	2013		2012
Revenues by Organizational Units BD Medical
Medical Surgical Systems	$	579	$	536
Diabetes Care		264		243
Pharmaceutical Systems		221		205
Total		1,064		983
BD Diagnostics
Preanalytical Systems		347		335
Diagnostic Systems		325		317
Total		672		652
BD Biosciences		279		265
Total Revenues	$	2,015	$	1,900

Revenues by Geographic Areas

Revenues by geographic areas were as follows:

	Three Months Ended December 31,
	2013		2012
Total Revenues
United States	$	849	$	830
International		1,166		1,070
Total Revenues	$	2,015	$	1,900